Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)
The Korean Journal of Internal Medicine
;
: 24-27, 2007.
Article
in English
| WPRIM
| ID: wpr-199149
ABSTRACT
Behcet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Remission Induction
/
Gastrointestinal Agents
/
Behcet Syndrome
/
Tumor Necrosis Factor-alpha
/
Treatment Outcome
/
Colectomy
/
Disease Progression
/
Gastrointestinal Diseases
/
Antibodies, Monoclonal
Limits:
Humans
/
Male
Language:
English
Journal:
The Korean Journal of Internal Medicine
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS